A POWER Study Published

As presented at numerous conferences, ritonavir-boosted darunavir was more effective than comparator PIs in treatment-experienced patients.

Last summer, based on the results of the three POWER studies, the FDA approved the PI darunavir for use in treatment-experienced patients. Now, results from the POWER 1 study have finally been published.

Patients were eligible for the study if they had evidence of virologic failure (>1000 copies/mL), prior exposure to all three major drug classes, and at least one major PI resistance mutation. Enrolled patients were randomized to receive an optimized background regimen plus either ritonavir-boosted darunavir (at 1 of 4 doses) or an investigator-selected comparator PI. The 318 patients treated (mean viral load, 4.5 log copies/mL; median CD4 count, 179 cells/mm³) were highly treatment-experienced, and approximately 60% had virus resistant to a…

Reviewing Author

Paul E. Sax, MD

A POWER Study Published

Topics

Reviewing Author